Page last updated: 2024-11-08

tremulacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tremulacin: extracted from Folia Populus tomentosa Carr; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
PopulusgenusA plant genus of the family SALICACEAE. Balm of Gilead is a common name used for P. candicans, or P. gileadensis, or P. jackii, and sometimes also used for ABIES BALSAMEA or for COMMIPHORA.[MeSH]SalicaceaeA plant family of the order MALPIGHIALES, superorder ROSANAE, class MAGNOLIOPSIDA. The leaves are alternate and simple, and staminate (male) flowers consist of one to several stamens; pistillate (female) flowers consist of a single-chambered ovary with several ovules that produce silky seeds.[MeSH]
Populus tomentosaspecies[no description available]SalicaceaeA plant family of the order MALPIGHIALES, superorder ROSANAE, class MAGNOLIOPSIDA. The leaves are alternate and simple, and staminate (male) flowers consist of one to several stamens; pistillate (female) flowers consist of a single-chambered ovary with several ovules that produce silky seeds.[MeSH]
Populus tomentosaspecies[no description available]SalicaceaeA plant family of the order MALPIGHIALES, superorder ROSANAE, class MAGNOLIOPSIDA. The leaves are alternate and simple, and staminate (male) flowers consist of one to several stamens; pistillate (female) flowers consist of a single-chambered ovary with several ovules that produce silky seeds.[MeSH]

Cross-References

ID SourceID
PubMed CID442544
CHEMBL ID462996
CHEBI ID9657
SCHEMBL ID1055476
MeSH IDM0251288

Synonyms (27)

Synonym
ACON1_001370
MEGXP0_001328
NCGC00180579-01
MLS001424184 ,
smr000469223
C09973
tremulacin
29836-40-6
HMS2052M17
BRD-A61856038-001-01-2
CHEMBL462996
chebi:9657 ,
[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[2-[(1-hydroxy-6-oxocyclohex-2-ene-1-carbonyl)oxymethyl]phenoxy]oxan-3-yl] benzoate
AC1L9D1T ,
beta-d-glucopyranoside, 2-(((((1-hydroxy-6-oxo-2-cyclohexen-1-yl)carbonyl)oxy)methyl)phenyl), 2-benzoate
HMS2232H17
CCG-101133
AB00698351-05
NC00383
SCHEMBL1055476
tremulacin(8ci)
surecn1055476
[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[2-[(1-hydroxy-6-oxo-cyclohex-2-ene-1-carbonyl)oxymethyl]phenoxy]tetrahydropyran-3-yl] benzoate
(2s,3r,4s,5s,6r)-4,5-dihydroxy-2-(2-((1-hydroxy-6-oxocyclohex-2-enecarbonyloxy)methyl)phenoxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3-yl benzoate
Q27108460
{2-[(2-o-benzoylhexopyranosyl)oxy]phenyl}methyl 1-hydroxy-6-oxocyclohex-2-ene-1-carboxylate
DTXSID10952263

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
glycosideA glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID401232Antiviral activity against HSV12004Journal of natural products, Apr, Volume: 67, Issue:4
Isolation of salicin derivatives from Homalium cochinchinensis and their antiviral activities.
AID401234Antiviral activity against HIV12004Journal of natural products, Apr, Volume: 67, Issue:4
Isolation of salicin derivatives from Homalium cochinchinensis and their antiviral activities.
AID401233Antiviral activity against HSV22004Journal of natural products, Apr, Volume: 67, Issue:4
Isolation of salicin derivatives from Homalium cochinchinensis and their antiviral activities.
AID385238Inhibition of COX2 at 10 uM2008Journal of natural products, May, Volume: 71, Issue:5
Itosides J-N from Itoa orientalis and structure - anti-COX-2 activity relationship of phenolic glycosides.
AID378799ABTS radical scavenging activity assessed as Trolox equivalent antioxidant capacity index2006Journal of natural products, Sep, Volume: 69, Issue:9
Phenolic glycosides with antioxidant activity from the stem bark of Populus davidiana.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's7 (50.00)29.6817
2010's6 (42.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.81 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.25 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]